Neurology · MigraineTrial Updateclinicalmid-term

APT Comparison Study to Evaluate Atogepant vs. Topiramate and Propranolol for Migraine Prevention

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AbbVie24 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 12:30:46 AM

Assessment confidence: 75% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The APT Comparison Study is critical as it evaluates atogepant against established migraine treatments, potentially reshaping treatment guidelines and market dynamics. Positive outcomes could significantly enhance atogepant's market position and compel competitors to adjust their strategies accordingly. Regulatory context from FDA (FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 22 ranked evidence items (13 high-relevance).

Strategic Assessment

Positive results may enhance atogepant's market share and influence treatment guidelines, prompting competitors to reassess their strategies. The strongest clinical anchor is Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study (ClinicalTrials.gov), entity match (abbvie). In Neurology · Migraine, 7 regulatory and 3 competitive items passed relevance filtering for AbbVie.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Biogen's Felzartamab Study Targets Isolated Microvascular Inflammation in Kidney Transplant Patients. This study could position atogepant favorably against established treatments, impacting market dynamics for migraine therapeutics.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG) (FDA). Entity match (propranolol); Regulatory pathway relevance (nda). The study's findings may influence future regulatory considerations and treatment guidelines, potentially affecting approval processes for migraine therapeutics.

Key Risks

Elevated medium regulatory exposure for AbbVie could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If atogepant demonstrates superior effectiveness and tolerability, it could capture a larger share of the migraine prevention market, impacting revenue for both AbbVie and competitors.
Upside for AbbVie may improve if Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial. (PubMed) delivers favorable follow-through.
Positive results may enhance atogepant's market share and influence treatment guidelines, prompting competitors to reassess their strategies.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and participant feedback on medication tolerability and effectiveness.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (propranolol); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TOPIRAMATE (SUPPL)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (propranolol); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TOPIRAMATE (SUPPL)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (propranolol); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE (SUPPL)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TOPIRAMATE (ORIG)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View source

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
ClinicalTrials.govhigh relevance
Entity match (abbvie)
FDA document
View source
Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Clinical Study on the Safety and Efficacy of Wide-Band Ultrasound Combined With Traditional Chinese Medicine Preparations in the Prevention and Treatment of Keloids
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Migraine Attack Pain Phase Prediction Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Biogen's Felzartamab Study Targets Isolated Microvascular Inflammation in Kidney Transplant Patients
Humanexa Signalsmedium relevance
Moderate corpus alignment
Psilocybin Shows Promise in Preventing Relapse in Alcohol Use Disorder with Depression
Humanexa Signalsmedium relevance
Moderate corpus alignment

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Compliance with preoperative antibiotic prophylaxis in cesarean delivery and its impact on surgical site infections: A national retrospective study of Jordan.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AbbVie
Atogepant
Topiramate
Propranolol

Commercial impact

medium

If atogepant demonstrates superior effectiveness and tolerability, it could capture a larger share of the migraine prevention market, impacting revenue for both AbbVie and competitors.

Regulatory impact

medium

The study's findings may influence future regulatory considerations and treatment guidelines, potentially affecting approval processes for migraine therapeutics.

What to watch

Monitor trial results and participant feedback on medication tolerability and effectiveness.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.